Pink Sheet is part of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction
UsernamePublicRestriction

J&J Celebrates Simponi Approval With Schering – For Now

This article was originally published in The Pink Sheet Daily

Executive Summary

As Schering waits to see if partner J&J will challenge Merck merger, FDA clears once-monthly follow-on to Remicade.

You may also be interested in...



Remicade: A Study In Translational Looping

The lifecycle of J&J’s TNF inhibitor Remicade – a “pipeline in a product” – highlights how the company used the knowledge gained from one product to improve and expand its portfolio.

NICE Gives Thumbs Down to Simponi--For Now

The controversial health technology assessment agency is unconvinced of the drug's cost benefit in a crowded market, which is already well served, and concerned about its long-term safety profile.

NICE Gives Thumbs Down to Simponi--For Now

The controversial health technology assessment agency is unconvinced of the drug's cost benefit in a crowded market, which is already well served, and concerned about its long-term safety profile.

Related Content

Topics

UsernamePublicRestriction

Register

LL1121650

Ask The Analyst

Ask the Analyst is free for subscribers.  Submit your question and one of our analysts will be in touch.

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel